New drug design targets a specific protein to block cancer signaling
Researchers developed a covalent inhibitor to more effectively block ARAF-driven signaling.
Scientists developed a more potent inhibitor called TWG-07-148. This drug targets ARAF-driven mitogen-activated protein kinase kinase (MEK) signaling.
The RAS/RAF/MEK/extracellular signal-regulated kinase pathway is often activated in cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes.
Researchers profiled seven allosteric MEK inhibitors. They found most potently inhibited CRAF-driven MEK activation but relatively spared ARAF-driven activation.
They used a rational design approach to create the new inhibitor. This acrylamide-containing analog of the MEK inhibitor trametinib targets Cys 514.
Cys 514 is a residue unique to ARAF. A cryo-electron microscopy structure shows how the drug covalently targets this residue.
The study highlights how the activating RAF isoform determines MEK inhibitor sensitivity. This provides proof of concept for developing inhibitors that block ARAF-driven signaling.
Key facts
- Most allosteric MEK inhibitors inhibit CRAF-driven activation more than ARAF-driven activation.
- The new inhibitor TWG-07-148 targets the unique Cys 514 residue in ARAF.
- Point mutations near the binding site can change how sensitive the proteins are to inhibitors.